Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 18 and up Men only

500-mg vs 1000-mg Ceftriaxone for Uncomplicated Gonorrhea

Official title: 500-mg Versus 1000-mg Ceftriaxone for Uncomplicated Gonorrhea Infection: A Noninferiority Randomized Controlled Trial

Run by National Taiwan University Hospital · NCT07710118 · Data updated 2026-11-12

This study tests whether a 500-mg dose of ceftriaxone works as well as a 1000-mg dose for treating uncomplicated gonorrhea in men.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexMen only
Enrollment400 (estimated)
SponsorNational Taiwan University Hospital
Academic / other
Locations1 site (Taipei)
StatusRecruiting
StartedJuly 2026
Main results expectedDecember 2028
Study endsJune 2029
Registry record updatedJuly 17, 2026
Trial IDNCT07710118 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Men 18 years and older with confirmed uncomplicated gonorrhea at oropharyngeal, anorectal, or urogenital sites.

Probably not a fit

Patients with complicated gonorrhea, co-infections requiring different therapy, or ceftriaxone allergy may not benefit from the tested doses.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 3 noninferiority randomized trial comparing two ceftriaxone doses for uncomplicated gonorrhea in men. Participants are adults with oropharyngeal, anal, or urogenital gonorrhea confirmed by culture or a positive NAAT. The study aims to determine if the lower dose achieves similar cure rates to the higher dose while avoiding unnecessary higher-dose exposure. Exclusions include complicated gonorrhea, recent systemic antibiotic use, and co-infection with certain pathogens or ceftriaxone allergy. The trial is conducted at multiple centers in Taiwan and is sponsored by National Taiwan University Hospital with several collaborating sites.

Why it matters

Potential benefit: If successful, the lower ceftriaxone dose could reduce drug exposure and potential side effects while maintaining effectiveness.

How similar studies have gone: Noninferiority trials comparing antibiotic dosing for gonorrhea have shown mixed results; this study addresses a specific dosing comparison in uncomplicated cases.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 18 years or older man, and
* having oropharyngeal, anorectal or urogenital N. gonorrhoeae infection confirmed by culture or a positive NAAT

Exclusion Criteria:

* Suspicion of a complicated N. gonorrhoeae infection. Complicated N. gonorrhoeae infection is defined as the presence of epididymitis, arthritis, bacteremia, conjunctivitis, or disseminated gonococcal infection.
* Use of systemic cephalosporins, doxycycline, or azithromycin at the screening visit or within 30 days prior to the enrollment visit is prohibited. Participants who require immediate antibiotic treatment at the screening visit, based on clinician judgment or shared decision-making with the participant, without awaiting PCR or culture confirmation, will be excluded from the study. Use of doxycycline for post-exposure prophylaxis (Doxy-PEP) is permitted.
* A NAAT test positive for C. trachomatis or M. genitalium at the screening visit.
* A history of allergy or intolerance to ceftriaxone, penicillins, or lidocaine, in alignment with the contraindications listed in the Sintrix (ceftriaxone) injection package insert. Allergy or intolerance is defined as the occurrence of adverse symptoms following antibiotic administration, including but not limited to skin rash, pruritus, dyspnea, angioedema, anaphylaxis, dizziness, nausea, vomiting, headache, or diarrhea. Laboratory abnormalities include cytopenias, eosinophilia, and elevated levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, or creatinine. Penicillins include natural penicillins (e.g., penicillin G), aminopenicillins (e.g., amoxicillin, ampicillin), penicillinase-resistant penicillins (e.g., oxacillin, dicloxacillin), extended-spectrum penicillins (e.g., piperacillin), and other agents classified within the penicillin class.

Where it's running

  • National Taiwan University Hospital
    Taipei, Taiwan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.